Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Akero Therapeutics Inc (AKRO)

26.24   0.43 (1.67%) 10-23 23:33
Open: 26.04 Pre. Close: 25.81
High: 26.4699 Low: 25.74
Volume: 115,116 Market Cap: 911M
Akero Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 10 full-time employees. The firm is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 26.515 - 26.642 26.642 - 26.757
Low: 25.427 - 25.575 25.575 - 25.709
Close: 25.996 - 26.239 26.239 - 26.46

Technical analysis

as of: 2020-10-23 4:40:25 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 37.85     One year: 42.84
Support: Support1: 25.50    Support2: 21.21
Resistance: Resistance1: 32.41    Resistance2: 36.68
Pivot: 27.99
Moving Average: MA(5): 26.38     MA(20): 28.59
MA(100): 31.89     MA(250): 25.64
MACD: MACD(12,26): -1.70     Signal(9): -1.53
Stochastic oscillator: %K(14,3): 7.82     %D(3): 8.32
RSI: RSI(14): 31.66
52-week: High: 41.16  Low: 10.78  Change(%): 29.8
Average Vol(K): 3-Month: 18573  10-Days: 20694

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
AKRO has closed above bottom band by 15.8%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 21 Oct 2020
Akero Therapeutics To Present At Upcoming Conferences In November - Yahoo Finance

Fri, 16 Oct 2020
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH - PRNewswire

Wed, 07 Oct 2020
Is Akero Therapeutics Inc (AKRO) Stock a Great Value? - InvestorsObserver

Wed, 30 Sep 2020
H.C. Wainwright Stick to Their Buy Rating for Akero Therapeutics Inc -

Wed, 30 Sep 2020
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study - PRNewswire

Tue, 29 Sep 2020
Chart Analysis: Get Key Insights on Akero Therapeutics, Inc. (AKRO) - Invest Million

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 35
Shares Float (M) 18
% Held by Insiders 9.51
% Held by Institutions 84.23
Shares Short (K) 984
Shares Short P. Month (K) 778

Stock Financials

EPS -2.080
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 3.610
Profit Margin
Operating Margin
Return on Assets (ttm) -27.7
Return on Equity (ttm) -45.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -59
Levered Free Cash Flow (M) -39

Stock Valuations

PE Ratio -12.62
PEG Ratio
Price to Book value 7.27
Price to Sales
Price to Cash Flow -15.50

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.